Table 3.
Characteristics of the patients with CRAB and CSAB before and after PSM.
| Baseline Characteristics | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| CSAB | CRAB | p-Value | CSAB | CRAB | p-Value | |
| Number of inpatient, n | 1280 | 1665 | 682 | 682 | ||
| Age in years, median (range) | 73 (0–100) | 68 (0–102) | <0.0001 | 70.5 (0–100) | 71 (0–102) | 0.845 |
| Sex male, n (%) | 917 (71.64) | 1127 (67.69) | 0.021 | 480 (70.38) | 480 (70.38) | 1.000 |
| Insurance, n (%) | 1030 (80.47) | 1167 (70.09) | <0.0001 | 500 (73.31) | 510 (74.78) | 0.537 |
| Number of diagnosis, median (range) | 6 (1–23) | 6 (1–24) | 0.02 | 6 (1–23) | 6 (1–24) | 0.243 |
| Charlson comorbidity index, median (range) | 5 (1–28) | 4 (1–18) | <0.0001 | 5 (1–16) | 5 (1–17) | 0.352 |
| Admission to ICU, n (%) | 160 (12.50) | 825 (49.55) | <0.0001 | 160 (23.46) | 170 (24.93) | 0.527 |
| Surgery, n (%) | 380 (29.69) | 753 (45.23) | <0.0001 | 250 (36.66) | 246 (36.07) | 0.822 |
| Myocardial infarction, n (%) | 34 (2.66) | 47 (2.82) | 0.784 | 24 (3.52) | 22 (3.23) | 0.764 |
| Congestive heart failure, n (%) | 250 (19.53) | 247 (14.83) | 0.001 | 115 (16.86) | 123 (18.04) | 0.568 |
| Peripheral vascular disease, n (%) | 21 (1.64) | 36 (2.16) | 0.309 | 20 (2.93) | 18 (2.64) | 0.742 |
| Cerebrovascular diseases, n (%) | 676 (52.81) | 1002 (60.18) | <0.0001 | 389 (57.04) | 380 (55.72) | 0.623 |
| Dementia, n (%) | 42 (3.28) | 41 (2.46) | 0.183 | 33 (4.84) | 21 (3.08) | 0.096 |
| Chronic pulmonary disease, n (%) | 342 (26.72) | 306 (18.38) | <0.0001 | 138 (20.23) | 163 (23.90) | 0.103 |
| Connective tissue disease, n (%) | 21 (1.64) | 22 (1.32) | 0.474 | 10 (1.47) | 6 (0.88) | 0.314 |
| Mild liver disease, n (%) | 42 (3.28) | 56 (3.36) | 0.902 | 26 (3.81) | 22 (3.23) | 0.557 |
| Peptic ulcer disease, n (%) | 34 (2.66) | 51 (3.06) | 0.513 | 21 (3.08) | 20 (2.93) | 0.874 |
| Diabetes mellitus, n (%) | 295 (23.05) | 354 (21.26) | 0.247 | 160 (23.46) | 152 (22.29) | 0.606 |
| Diabetes mellitus with chronic complications, n (%) | 39 (3.05) | 19 (1.14) | <0.0001 | 10 (1.47) | 14 (2.05) | 0.410 |
| Moderate to severe chronic kidney disease, n (%) | 100 (7.81) | 160 (9.61) | 0.088 | 61 (8.94) | 54 (7.92) | 0.495 |
| Hemiplegia, n (%) | 15 (1.17) | 31 (1.86) | 0.134 | 12 (1.76) | 11 (1.61) | 0.833 |
| Solid tumor without metastases, n (%) | 121 (9.45) | 72 (4.32) | <0.0001 | 32 (4.69) | 45 (6.60) | 0.127 |
| Leukemia, n (%) | 18 (1.41) | 4 (0.24) | <0.0001 | 2 (0.29) | 3 (0.44) | 1.000 |
| Malignant lymphoma, n (%) | 13 (1.02) | 7 (0.42) | 0.051 | 1 (0.15) | 3 (0.44) | 0.624 |
| Severe liver disease, n (%) | 15 (1.17) | 25 (1.50) | 0.444 | 11 (1.61) | 6 (0.88) | 0.222 |
| Metastatic tumor, n (%) | 94 (7.34) | 26 (1.56) | <0.0001 | 12 (1.76) | 21 (3.08) | 0.113 |
CRKP: carbapenem resistant Acinetobacter baumannii, CSKP: carbapenem susceptible A. baumannii, PSM: propensity score matching, ICU: intensive care unit.